Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENDURE: Kuvan Responsiveness in PKU
NCT01082328Phase 4Completed
- Sponsor
- Merck KGaA
- Start
- May 2010
- Primary completion
- May 2012
- Modality
- Allosteric Modulators, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 4 trial of sapropterin in phenylketonuria (PKU), sponsored by Merck KGaA. Started May 2010; status: completed.
02
Drugs
sapropterin
03
Conditions
phenylketonuria (PKU)
Beyond the preview
Go deeper on NCT01082328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01082328.